- Home
- STEC vs BOLD Comparison
STEC vs BOLD Comparison
Compare STEC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- BOLD
- Stock Information
- Founded
- STEC 2006
- BOLD 2018
- Country
- STEC Hong Kong
- BOLD United States
- Employees
- STEC N/A
- BOLD N/A
- Industry
- STEC
- BOLD
- Sector
- STEC
- BOLD
- Exchange
- STEC NYSE
- BOLD Nasdaq
- Market Cap
- STEC 63.8M
- BOLD 24.4M
- IPO Year
- STEC 2021
- BOLD 2024
- Fundamental
- Price
- STEC $0.74
- BOLD $1.19
- Analyst Decision
- STEC
- BOLD Buy
- Analyst Count
- STEC 0
- BOLD 3
- Target Price
- STEC N/A
- BOLD $4.00
- AVG Volume (30 Days)
- STEC 10.9K
- BOLD 105.1K
- Earning Date
- STEC 08-05-2025
- BOLD 08-11-2025
- Dividend Yield
- STEC N/A
- BOLD N/A
- EPS Growth
- STEC N/A
- BOLD N/A
- EPS
- STEC N/A
- BOLD N/A
- Revenue
- STEC $10,672,000.00
- BOLD N/A
- Revenue This Year
- STEC $9,392.20
- BOLD N/A
- Revenue Next Year
- STEC N/A
- BOLD N/A
- P/E Ratio
- STEC N/A
- BOLD N/A
- Revenue Growth
- STEC N/A
- BOLD N/A
- 52 Week Low
- STEC $0.20
- BOLD $1.00
- 52 Week High
- STEC $3.25
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- STEC 40.44
- BOLD N/A
- Support Level
- STEC $0.70
- BOLD N/A
- Resistance Level
- STEC $0.80
- BOLD N/A
- Average True Range (ATR)
- STEC 0.08
- BOLD 0.00
- MACD
- STEC 0.00
- BOLD 0.00
- Stochastic Oscillator
- STEC 38.55
- BOLD 0.00
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. It has two revenue segments Wealth management service and Asset management service. Key revenue is generated from Wealth management service.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.